Cost-utility of treatments for pulmonary arterial hypertension: A Markov state-transition decision analysis model

Clinical Drug Investigation

Volumn 29, Issue 10, 2009, Pages 635-646

  Garin, Margaret C ^a   Clark, Leslie ^b   Chumney, Elinor C G ^c   Simpson, Kit N ^d   Highland, Kristin B ^e  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c BELMONT UNIVERSITY   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; GABAPENTIN; ILOPROST; OXYCODONE PLUS PARACETAMOL; PLACEBO; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNIPROST;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG DOSE INCREASE; HEALTH CARE COST; HUMAN; LIVER FUNCTION; MEDICAID; MEDICAL DECISION MAKING; MEDICARE; PAIN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; SIDE EFFECT; TREATMENT DURATION;

ANTIHYPERTENSIVE AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION, PULMONARY; MARKOV CHAINS; MEDICAID; MEDICARE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 69549103334     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11317820-000000000-00000     Document Type: Article

References (33)

1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987 Aug; 107 (2): 216-223 (Pubitemid 17137857)
2. Rubin LJ. Primary pulmonary hypertension. Chest 1993 Jul; 104 (1): 236-250
3. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991 Sep 1; 115 (5): 343-349
4. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004 Jul; 126 Suppl. 1: 78-92
5. Narine L, Hague LK, Walker JH, et al. Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension. Curr Med Res Opin 2005 Dec; 21 (12): 2007-2016 (Pubitemid 41803112)
6. Highland KB, Strange C, Mazur J, et al. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest 2003 Dec; 124 (6): 2087-2092 (Pubitemid 38010573)
7. Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004 Jul; 126 Suppl. 1: 7-10
8. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002 Mar 21; 346 (12); 896-903 (Pubitemid 34984638)
9. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002 Mar 15; 165 (6): 800-804 (Pubitemid 34229650)
10. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996 Feb 1; 334 (5): 296-301
11. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002 Aug 1; 347 (5): 322-329 (Pubitemid 34815354)
12. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005 Nov 17; 353 (20): 2148-2157 (Pubitemid 41653106)
13. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004 Feb 15; 169 (4): 441-447 (Pubitemid 38187114)
14. Oudiz RJ, Torres F, Frost AE, et al. ARIES-1: a placebo-controlled, efficacy and safety study of ambrisentan in patients with pulmonary arterial hypertension [abstract]. Chest 2006; 130 Suppl. 4: 121
15. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000 Feb; 161 (2 Pt 1): 487-492 (Pubitemid 30129457)
16. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006 Dec 1; 174 (11): 1257-1263 (Pubitemid 44924827)
17. Hoeper MM, Oudiz RJ, Peacock A, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004 Jun 16; 43 Suppl. S: 48-55 (Pubitemid 38759717)
18. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year; in search of a standard. Med Decis Making 2000 Jul-Sep; 20 (3): 332-342 (Pubitemid 30479101)
19. Keogh AM, McNeil KD, Wlodarczyk J, et al. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant 2007 Feb; 26 (2): 181-187 (Pubitemid 46136035)
20. Drug topics red book. Oradell (NJ): Medical Economics Co., 2006
21. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med 2000 Mar 21; 132 (6): 425-434
22. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999 Apr 13; 99 (14): 1858-1865 (Pubitemid 29181415)
23. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002 Aug 21; 40 (4): 780-788 (Pubitemid 34925627)
24. Letairis prescribing information. Foster City (CA): Gilead, 2009 Jul
25. Tracleer prescribing information. Actelion Pharmaceuticals US, Inc., San Francisco (CA): Mar 2009
26. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007 Jun; 131 (6): 1917-1928 (Pubitemid 46981654)
27. Keogh AM, Jabbour A, Weintraub R, et al. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2007 Nov; 26 (11): 1079-1083 (Pubitemid 350088508)
28. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med 2005 Jun 1; 171 (11): 1292-1297 (Pubitemid 40740738)
29. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006 May 16; 47 (10): 2049-2056
30. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006 Mar; 129 (3): 683-688
31. Laliberte K, Arneson C, Jeffs R, et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004 Aug; 44 (2): 209-214 (Pubitemid 38982164)
32. Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007 Jun; 153 (6): 1037-1047 (Pubitemid 46809838)
33. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003 Jun 18; 41 (12): 2119-2125 (Pubitemid 36724255)